Medartis has acquired the remaining stake in KeriMedical and completed a PPA

July 2025 — Medartis Holding AG has acquired the remaining stake in KeriMedical S.A., gaining full access to an innovative hand portfolio, strengthening its technological expertise in joint replacement and broadening its global surgeon network. Following the transaction, a purchase price allocation (PPA) in accordance with IFRS 3 was prepared for accounting purposes.

Headquartered in Basel, Switzerland, Medartis is a leading global manufacturer and provider of medical devices for the surgical fixation of bone fractures of the upper and lower extremities as well as the craniomaxillofacial region. The company was founded in 1997 and employs approximately 1,200 people across 13 locations, with products sold in over 50 countries worldwide. Medartis is committed to providing surgeons and operating theater personnel with innovative titanium implants and instruments, complemented by best-in-class service.

Founded in 2016, KeriMedical specializes in the development and commercialization of a comprehensive range of implants exclusively for hand and wrist surgery. The company’s team has extensive experience in orthopedic surgery with expertise across all operational areas, including design, manufacturing, quality, marketing and product promotion. It collaborates closely with a panel of internationally recognized surgeons. KeriMedical is headquartered in Geneva, employs approximately 150 people and its products are available in 30 countries.

Our role in the transaction

Oaklins’ team in Switzerland supported Medartis in the post-transaction phase by preparing a PPA in accordance with IFRS 3. The report included the allocation of the purchase price to identifiable acquired assets, assumed liabilities and goodwill.